Page 162 - 16Neonatal Jaundice_compressed
P. 162

Treatment





                          Recommendations – 7.3 Exchange transfusion

                          Use a double-volume exchange transfusion to treat babies:
                          •   whose serum bilirubin level indicates its necessity (see threshold table (Section 1.3) and
                            treatment threshold graphs (Section 1.6))
                           and/or
                          •   with clinical features and signs of acute bilirubin encephalopathy.
                          During exchange transfusion do not:
                          •   stop continuous multiple phototherapy
                          •   perform a single-volume exchange
                          •   use albumin priming
                          •   routinely administer intravenous calcium.
                          Following exchange transfusion:
                          •   maintain continuous multiple phototherapy
                          •   measure serum bilirubin level within 2 hours and manage according to threshold table
                            (Section 1.3) and treatment thresholds graphs (Section 1.6).


              7.4        Other treatments


                          Clinical questions
                          What are the other ways of treating hyperbilirubinaemia? Are they effective?
                          What is the effectiveness of the following interventions in treating neonatal
                          hyperbilirubinaemia/preventing kernicterus?
                          – metalloporphyrins
                          – gammaglobulins
                          –  drugs (phenobarbitol, clofibrate, cholestyramine)
                          – agar, charcoal
                          –  suppositories, other rectal modes of treatment
                          –  complementary/alternative medicines (Chinese herbal remedies such as Yin-chen)

                         Following electronic searches, which  were restricted to controlled trials and reviews, 167
                         records were identified and 22 hard-copy articles were requested. These were supplemented by
                         relevant articles identified by earlier searches for the phototherapy review. A total of 61 hard-
                         copy articles were obtained. For some interventions,  no RCTs were identified so other study
                         types were used in these analyses.

              7.4.1      Intravenous immunoglobulin
                         Intravenous immunoglobulin (IVIG) acts by preventing the destruction of sensitised erythrocytes.
                         IVIG contains pooled IgG  immunoglobulins extracted from the  plasma of over  1000 blood
                         donors. The  Department of Health has recently updated their guidance on the use of IVIG
                         (www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_
                         085235).

                         Description of included studies
                         Eleven articles were obtained, including reports of five RCTs 205-209  carried out in Argentina, 205
                                  207
                         Germany,  Iran,  Saudi Arabia  and Turkey   208  comparing IVIG in combination with
                                                        206
                                         209
                         phototherapy with phototherapy alone for the treatment of haemolytic jaundice. Six articles
                         were excluded for the following reasons: not randomised (two studies), compared different
                         dosages of IVIG (one), examined IVIG as prophylaxis to prevent the need for  phototherapy
                         (one), non-English language (one) and conference abstract (one).
                         One study  reported using random numbers to allocate the babies into the treatment groups
                                  208
                         and using sealed envelopes to conceal the treatment allocation and so was rated EL 1++. None
                         of the other studies reported the method of randomisation or allocation concealment and so


                                                                                                        131
   157   158   159   160   161   162   163   164   165   166   167